[Heavyweight] The first domestically produced Class 1 new anti-ED drug, AIRIS®, is on the market, and Yuekang Pharmaceutical has stepped up its innovation and upgrade

On December 27, 2021, Yuekang Pharmaceutical Group Co.
, Ltd.
's 1.
1-type new drug Alex® Aldenafil Citrate Tablets was officially approved (National Medicines Standard H20210051).
This product is the first domestic product with independent intellectual property rights.
The PDE-5 inhibitor has significant clinical efficacy
.

The company said that after the product goes on the market, it will work through multiple channels simultaneously, and the new drug is expected to become a dazzling star in the field of anti-ED

Major national special projects have been patented in many countries! Yuekang Class 1 new drug approved

The Class 1.
1 new drug Alison® Aldenafil Citrate approved this time is a new generation of PDE-5 inhibitor for the treatment of male erectile dysfunction (ED)
.

The new drug has the pharmacokinetic characteristics of rapid oral absorption, stable drug effect, and not affected by high-fat diet

It is reported that Adenafil Citrate Tablets of Yuekang Pharmaceutical Group is a major special project of the Ministry of Science and Technology of the "863" Plan of the "Tenth Five-Year Plan" and a major new drug creation project in the "Twelfth Five-Year Plan".
Patent in many countries and regions such as Russia, Japan, Canada, South Korea and so on
.

In recent years, Yuekang Pharmaceutical Group has continued to increase its innovation and upgrading.
In 2020, R&D investment will exceed 150 million yuan, and R&D investment in the first three quarters of 2021 will increase by 58.
28% year-on-year
.

According to annual report data, in addition to the newly approved Aldenafil Citrate Tablets, the company also has a number of blockbuster new drugs under development, such as China’s first completely independent research and development for the treatment of primary hepatocellular carcinoma.

Good effect, high safety, low side effects! New product launches and multi-channel simultaneous efforts

As a domestic patented new anti-ED drug, AIRIS® Aldenafil Citrate Tablets has the advantages of good patient experience, high safety, and low side effects compared with similar products on the market
.

AIRIS® Aldenafil Citrate Tablets is the first domestic product to use the RigiScan Plus for clinical monitoring of subjects
.

After the subject wears the instrument, the erection hardness and circumference change of the penis can be monitored in real time, and displayed through data, and the treatment effect can be evaluated through objective index measurement, which is more scientific than the previous subjective index evaluation through scales.

The 60mg test results of Aldenafil Citrate Tablets showed that for the main curative index, the duration of the erection hardness of the head and root of the penis in the test group was more than 4 times that of the control group; the secondary curative index, erection at the root of the penis The duration of time hardness ≥80%, the time required for the head of the penis to be erected to hardness ≥60%, Aldenafil citrate tablets were superior to the control group
.

For high-dose drug users, the incidence of adverse reactions of traditional anti-ED products was relatively high in the past, which affected the patient's medication experience
.

Alex® Aldenafil Citrate Tablets have obvious characteristics in chemical structure, and have strong and specific interaction with PDE-5.

As a new class 1 anti-ED drug, Yuekang Pharmaceutical Group has high expectations for Alix® Aldenafil Citrate Tablets
.

According to reports, Yuekang Pharmaceutical Group has completed the product development plan and the product will be put into operation immediately after approval

The scale of my country's innovative drug market has exceeded 100 billion, and the anti-ED field ushered in the first domestically-made 1.
1 new drug

In recent years, as innovation has become the main theme of national development, coupled with the repeated impact of the new medical reform policy on generic drugs, the research and development of innovative drugs has become a key point of competition among pharmaceutical companies, and China's innovative drug market is ushering in a new period of outbreak
.

According to data from Minai.
com, in 2020, the market size of innovative drugs will be more than 100 billion yuan in China’s urban public hospitals, county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions).
System optimization and medical insurance negotiations have increased the policy preference for innovative drugs.
It is estimated that the market size is expected to exceed 800 billion yuan by 2029.
With such a huge market space, only the brave and the strong can have a share
.

More than 50 Class 1 new drugs have been approved for marketing since 2020.
Among the 34 new chemical drugs Class 1 drugs, anti-tumor and immunomodulators, and systemic anti-infective drugs are still the hottest competition among companies.
Kang Pharmaceutical Group's AIRIS® Aldenafil Citrate Tablets is the first Class 1.
1 new drug in the genitourinary system and sex hormone drugs
.

The total sales of major ED-resistant varieties in the past three years (unit: 100 million yuan)

Source: Minet database

The best-selling anti-ED varieties on the market include sildenafil, tadalafil, and vardenafil.
At present, it is mainly a competition between domestic brands and original research drugs
.

According to data from Menet.

From the perspective of listed brands, the sales of the original researched sildenafil and tadalafil tablets in China's public medical institutions will show a rapid decline in 2020, and the sales of physical pharmacies in Chinese cities will slowly rise, while some domestic brands Thanks to the new medical reform policy, the sales scale has shown a sustained and rapid increase.
It can be seen that with the improvement of domestic pharmaceutical companies' research and development capabilities, consumers' trust in domestic brands is gradually increasing
.

Alex® Aldenafil Citrate Tablets of Yuekang Pharmaceutical Group is a 1.
1-type new drug with a new chemical structure independently developed by China.
It is also the first domestically-made patented new drug in the field of anti-ED in recent years, which has epoch-making significance.

.

As the overall prevalence of ED increases year by year and is recognized and valued by more people, the market space for drugs is also expanding.